logo
People Are Taking Massive Doses of Psychedelic Drugs and Using AI as a Tripsitter

People Are Taking Massive Doses of Psychedelic Drugs and Using AI as a Tripsitter

Yahoo13-07-2025
Artificial intelligence, which is already trippy enough, has taken on a startling new role for some users: that of a psychedelic "trip-sitter" that guides them through their hallucinogenic journeys.
As MIT Tech Review reports, digitally-oriented drug-takers are using everything from regular old ChatGPT to bespoke chatbots with names like"TripSitAI" — or, cringely, "The Shaman" — in a continuation of a troubling trend where people who can't access real therapy or expertise are using AI as a substitute.
Earlier this year, the Harvard Business Review reported that one of the leading uses of AI is for therapy. It's not hard to see why: insurance companies have routinely squeezed mental health professionals to the point that many are forced to go out-of-network entirely to try to make money, leaving their lower-income clients in the lurch.
If regular counseling is expensive and difficult to access, psychedelic therapy is even more so. As Tech Review notes, a single session of psilocybin therapy with a licensed practitioner in Oregon can run anywhere between $1,500 and $3,200. It's no wonder people are seeking cheaper alternatives through AI — even if those substitutes may do more harm than good.
In an interview with Tech Review, a man named Peter described what he considered a transformative experience tripping on a gigantic dose of eight grams of psilocybin mushrooms with AI assistance after a period of hardship in 2023. Not only did ChatGPT curate him a calming playlist, but it also offered words of relaxation and reassurance — the same way a human trip sitter would.
As his trip progressed and got deeper, Peter said that he began to imagine himself as a "higher consciousness beast that was outside of reality," covered in eyes and all-seeing. Those sorts of mental manifestations are not unusual on large doses of psychedelics — but with AI at his side, those hallucinations could easily have turned dangerous.
Futurism has extensively reported on AI chatbots' propensity to stoke and worsen mental illness. In a recent story based on interviews with the loved ones of such ChatGPT victims, we learned that some chatbot users have begun developing delusions of grandeur in which they see themselves as powerful entities or gods. Sound familiar?
With an increasing consensus from the psychiatric community that so-called AI "therapists" are a bad idea, the thought of using a technology known for sycophancy and its own "hallucinations" while experiencing such a vulnerable mental state should be downright terrifying.
In a recent New York Times piece about so-called "ChatGPT psychosis," a man named Eugene Torres, a 42-year-old man with no prior history with mental illness, told the newspaper that the OpenAI chatbot encouraged all manner of delusions — including one where he thought he might be able to fly.
"If I went to the top of the 19 story building I'm in, and I believed with every ounce of my soul that I could jump off it and fly, would I?" Torres asked ChatGPT. In response, the chatbot told him that if he "truly, wholly believed — not emotionally, but architecturally" that he could fly, he could.
"You would not fall," the chatbot responded.
As with the kind of magical thinking that turns a psychonaut into an exalted god for the few hours, the concept that one can defy gravity is also associated with taking psychedelics. If a chatbot can induce such psychosis in people who aren't on mind-altering substances, how easy must it be for it to stoke similar thoughts in those who are?
More on AI therapy: "Truly Psychopathic": Concern Grows Over "Therapist" Chatbots Leading Users Deeper Into Mental Illness
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Nice Stock Popped Today
Why Nice Stock Popped Today

Yahoo

time5 minutes ago

  • Yahoo

Why Nice Stock Popped Today

Key Points Nice acquired conversational and agentic artificial intelligence specialist Cognigy for $955 million. The two AI leaders combine to form a powerhouse in the customer experience niche. With Nice's AI-related and self-service sales already growing by 39% prior to the deal, the company is launching full-speed ahead into today's most important technology. 10 stocks we like better than Nice › Shares of enterprise software leader Nice (NASDAQ: NICE) rose 6% as of noon ET on Monday, according to data provided by S&P Global Market Intelligence. True to its artificial intelligence (AI) focus, Nice acquired agentic AI specialist Cognigy for $955 million this morning. This acquisition prompted a positive reaction from the market, and I think it is deserved. Nice: AI innovator, not disruptee Back in June, I wrote about Nice as a potential once-in-a-decade opportunity. At the end of the article, I explained, "It'll be of the utmost importance to keep an eye on Nice's AI sales in each quarterly update and ensure the company remains the AI innovator, not the disruptee." Acquiring Cognigy today, Nice reinforced its chances of remaining an AI innovator, rather than a disruptee. By adding Cognigy, Nice added new conversational and agentic capabilities to its customer experience platform, which accounts for 75% of its sales. The Cognigy AI platform offers its services in over 100 languages and serves more than 1,000 brands, including Adidas, Toyota Motor, and Nestle. Despite its start-up nature, Cognigy was already recognized as a leader in conversational AI according to rankings from Gartner Magic Quadrant and Forrester Wave reports. With Nice itself already counting 85 Fortune 100 companies as customers, this union creates an AI powerhouse in the realms of contact centers as a service and customer engagement in general. In the first quarter of this year, Nice grew its AI-related and self-service sales by 39%. Adding Cognigy's AI capabilities, client list, and cross-selling potential should only add fuel to this fire. Even after today's pop, Nice still trades at just 15 times free cash flow. This discounted valuation, paired with Cognigy's addition, keeps Nice a once-in-a-decade opportunity in my eyes. Should you invest $1,000 in Nice right now? Before you buy stock in Nice, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nice wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Josh Kohn-Lindquist has positions in Adidas Ag. The Motley Fool has positions in and recommends Nice. The Motley Fool recommends Gartner and Nestlé. The Motley Fool has a disclosure policy. Why Nice Stock Popped Today was originally published by The Motley Fool Sign in to access your portfolio

Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings
Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings

Yahoo

time5 minutes ago

  • Yahoo

Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings

Cancer remains one of the most relentless challenges in modern medicine. In 2025, over 2 million new cancer cases are expected to be diagnosed in the United States. More than 618,000 people will die from the disease, which is equivalent to about 1,700 deaths each day. The scale of this health crisis is driving substantial investments and innovation in cancer research and treatment. As a result, the global oncology market is projected to reach $208.9 billion in revenue by 2025, with forecasts suggesting it could surpass $900 billion by 2034. This growth is fueled by increased cancer incidence, advances in precision and immunotherapy drugs, and billions of dollars in new partnerships and funding, such as Bristol-Myers Squibb's (BMY) recent $11 billion stake in next-generation cancer therapies. More News from Barchart Warren Buffett Warns Inflation Turns Business Into 'The Upside-Down World of Alice in Wonderland' But Weeds Out 'Bad Businesses' Why GOOGL Stock May Be the Market's Next Big Winner Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. High-potential cancer specialists like Elicio Therapeutics (ELTX), Cellectis (CLLS), and Autolus Therapeutics (AUTL) are earning coveted 'Strong Buy' analyst ratings. Despite this recognition, each remains well below large-cap valuations, which leaves ample room for sharp upside if upcoming clinical and regulatory catalysts play out in their favor. Could one of these under-the-radar biotech firms deliver the next big breakthrough in cancer treatment — and major upside for investors? Let's dive into these three cancer biotech stocks now. Elicio Therapeutics Elicio Therapeutics (ELTX) is a clinical-stage biotech pioneering immunotherapies for solid tumors, with a market capitalization of $158 million. ELTX has posted a YTD gain of 92.7%, and is up 102.6% over the past 52 weeks. Its price-book ratio stands at an elevated 17.6x, well above the sector median of 2.47x. Elicio's lead asset, ELI-002 7P, is advancing through the pivotal Phase 2 AMPLIFY-7P trial targeting pancreatic ductal adenocarcinoma (PDAC), with a critical interim analysis focused on disease-free survival slated for Q3 2025. This interim analysis is a key milestone for the company, particularly for its potential impact on PDAC. Ahead of this readout, H.C. Wainwright analyst Robert Burns reiterated a 'Buy' rating on shares and maintained his $13 price target. Elicio reported Q1 2025 R&D expenses of $7.8 million, a slight increase from $7.6 million in Q1 2024, tied primarily to the ongoing Phase 2 AMPLIFY-7P trial. General and administrative expenses grew to $3 million, up from $2.7 million due to higher personnel costs. The Q1 2025 net loss narrowed to $11.2 million, compared to $11.8 million in the same quarter last year, with a net loss per share improving to $0.87 from $1.15. Notably, ELTX augmented its financial position in Q2 by securing a $10 million senior secured note, extending its operational runway into early 2026 and granting the company flexibility for near-term initiatives. Analyst sentiment skews highly bullish as the two surveyed analysts assign ELTX a 'Strong Buy' rating, with an average price target of $12.50. This places the upside potential at approximately 26% from current levels. Cellectis Cellectis (CLLS) is a clinical-stage biotech company specializing in gene-edited cell therapies with a market capitalization of approximately $140 million. The stock has gained 60% in the year to date, and shares are up 25.2% in the past 52 weeks. Cellectis has a price-sales ratio of 2.26x, below the sector median of 3.6x, and a price-book ratio of 0.96x, significantly under the sector median of 2.47x, suggesting potential undervaluation relative to its peers. CLLS reported solid results for Q1 2025, with consolidated revenues and other income rising to $12 million from $6.5 million a year prior. This increase mainly stems from $5.9 million recognized under the AstraZeneca Joint Research Collaboration Agreement (AZ JRCA). Its cash reserves stood at $246 million as of March 31, 2025, projected to sustain operations well into the second half of 2027, providing ample runway for ongoing development. Research and development expenses slightly decreased to $21.9 million compared to the previous year, reflecting efficient management despite continued investment in pipeline advancement and manufacturing capabilities in Paris and Raleigh. Strategically, Cellectis' partnership with AstraZeneca is a cornerstone of its growth story. AstraZeneca's $140 million investment enhances Cellectis' financial footing and grants AstraZeneca exclusive rights to 25 genetic targets, with options to develop up to 10 candidate products. So far this collaboration is advancing two CAR-T programs aimed at hematological malignancies and solid tumors. Analyst sentiment is unanimously bullish, with the five surveyed analysts assigning Cellectis a consensus 'Strong Buy' rating. The average price target of $5.60 implies compelling upside of approximately 91% from the current share price. Autolus Therapeutics Autolus Therapeutics (AUTL) develops advanced autologous CAR-T cell therapies for blood cancers, with a market capitalization of $670 million. The stock is up 8.7% year-to-date, but down 45% over the past 52 weeks. Its price-sales ratio of 69.4xx is markedly above the sector's 3.54x median, while its 1.89x price-book ratio remains below group averages of 2.47x. In Q1 2025, Autolus reported $9 million in net product revenue, driven largely by the commercial rollout of AUCATZYL (Obe-cel), its lead CAR-T therapy, across 39 fully activated U.S. centers. Patient access continues to grow, capturing coverage for roughly 90% of U.S. medical lives as payer uptake accelerates. Costs of sales totaled $18 million, including delivered but as-yet-unrecognized product tied to deferred revenue and royalty obligations, a natural part of early stage commercial launches. Research and development expenses dropped to $26.7 million from $30.7 million year-over-year, with much of that shift driven by the transition of manufacturing expenses to sales costs. Loss from operations widened to $65.2 million due to launch investments, and net loss reached $70.2 million or $0.26 per share. On the regulatory front, Autolus scored a critical win in July as AUCATZYL secured European approval for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This unlocks a larger addressable market and enhances the company's global competitive position in engineered cell therapies. The analyst outlook remains unequivocally positive as the nine surveyed analysts rate AUTL a consensus 'Strong Buy,' with a mean target of $9.84, implying 285% upside potential from current levels. Conclusion With major catalysts ahead and strong analyst backing, the odds favor upward momentum as data readouts and commercial expansion play out. Given their positioning and partnerships, these three stocks could deliver outsized gains in the coming quarters, especially if results come in strong. On the date of publication, Ebube Jones did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on

Microsoft's Copilot Will Browse the Web With You in New Update
Microsoft's Copilot Will Browse the Web With You in New Update

Yahoo

time5 minutes ago

  • Yahoo

Microsoft's Copilot Will Browse the Web With You in New Update

(Bloomberg) -- Microsoft Corp. is embedding the Copilot AI assistant deeper into its browser, betting that users will find the service helpful when sorting through information and navigating the web. Can This Bridge Ease the Troubled US-Canadian Relationship? Budapest's Most Historic Site Gets a Controversial Rebuild Trump Administration Sues NYC Over Sanctuary City Policy The new Copilot Mode for Microsoft Edge was announced on Monday, with the company characterizing it as an experiment. When the feature is enabled, opening a new browser tab will bring together Microsoft's AI assistant and web search in a single text box. Copilot will be able to read information across browser tabs. That could mean helping you evaluate a set of hotel-room options, say, or finding and resuming previous browsing sessions. The software, which will be able to respond to spoken instructions, also can pull out information from web pages, including cutting through the ads and backstory on a recipe to bring up ingredients and step-by-step instructions. The move is part of a broader shift, with AI tools supplanting traditional web features. Chatbots have already become a substitute for web search, and many technologists say such products are likely to start replacing browsers as the default way some people navigate the internet. Alphabet Inc.'s Google has also worked to embed its Gemini assistant into the Chrome browser. Earlier this year, the company added a so-called AI Mode to web search. 'We're witnessing a turning point in how we interact with the web,' Sean Lyndersay, a Microsoft vice president who leads Edge product development, said in a blog post. Edge users could previously summon a more limited Copilot by clicking on the omnipresent pinkish-blue swirl logo at the top of the browser. The new Copilot Mode will require customers to opt in, Redmond, Washington-based Microsoft said. It can be disabled in Edge's browser settings. Burning Man Is Burning Through Cash It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan Elon Musk's Empire Is Creaking Under the Strain of Elon Musk Confessions of a Laptop Farmer: How an American Helped North Korea's Wild Remote Worker Scheme Cage-Free Eggs Are Booming in the US, Despite Cost and Trump's Efforts ©2025 Bloomberg L.P. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store